<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873559</url>
  </required_header>
  <id_info>
    <org_study_id>Ethical protocol H-16020521</org_study_id>
    <nct_id>NCT02873559</nct_id>
  </id_info>
  <brief_title>Effect of PROGRESSive Training and Teststerone in Older Frail Men</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>Effect of PROGRESSive Resistance Training, Protein Supplements and Testosterone in Older Frail Men With Testosterone Deficiency (PROGRESS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this scientific clinical investigation we will test whether testosterone and progressive
      resistance training can improve muscle strength and reduce the risk of falls in older men. In
      addition, we will examine whether this treatment improves quality of life, functional
      capacity, including sexual function and counteracts depression. Such a project have not been
      performed earlier.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project background: In Denmark more than 1,000 people each year die of a fall, which is more
      than five times as many dying in traffic accidents. Fall accidents are also the leading cause
      of traumatic brain injury and is a relatively unnoticed problem, although this type of
      accidents causes more hospital bed days than all other accidents combined.

      Annually, almost half of the 375,000 elderly Danes over 75 years of age and relatively three
      times as many of the approximately 40,000 elderly people in nursing homes fall every year,
      causing over 40,000 hospital contacts annually. Ten percent of all elderly people
      hospitalized each year because of a fall, mostly with fractures, for which the risk increases
      fivefold after a fall. In Denmark there are now now around 1 million people over 65 years of
      age. Over the next 25 years we will experience a 50% growth to 1.5 million people over 65
      years of age.

      Injury, disability and death caused by falls is therefore a widespread and growing human and
      societal problem. Many will never recover completely and will therefore need help to cope
      with everyday life. After the first fall risk increase for repeated falls. Especially for
      older people living in their own homes permanent or temporary disabilities results in a
      severe deterioration of the quality of life. Treatment of falls is also a significant
      financial burden on health and social care.

      The main reason for the decline is muscle weakness. Muscle weakness leads to greatly
      increased risk of falling, decreased quality of life and functional capacity. Musclemass and
      -power decrease about 40 percent from age 20 to 80 years old.

      Recent studies have shown that even 90-year-old persons can double their muscle strength by
      intensive training just three times per week. The level of the male sex hormone testosterone
      decreases with age and leads to impaired muscle mass. Twenty percent of men over 60 and 50
      percent over 80 years, a low level of testosterone in total equivalent to more than 100,000
      Danes. From the human and socio-economic perspective, it is important to find treatments that
      can enhance function in the elderly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stand-up-and Sit-test</measure>
    <time_frame>up to 5 months (at study completion)</time_frame>
    <description>It is a measure of overall strength in the lower extremities. Result of the test is defined as the number of times the participant can stand up and sit from a chair in 30 seconds. There is a good correlation (r = 0.78) with a leg press and an acceptable test-retest reliability (ICC = 0.86).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of falls via questionaire</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>included in the monitoring of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Balance ability,</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Tandem Test containing three starting positions: 1) Standing with feet together, standing in the semi-tandem position and standing in the tandem stand. coupled with decrease risk of fall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avlund mobility scale</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Questions about experiencing fatigue and support needs of ordinary everyday activities. Avlund mobility scale is correlated with the isometric muscle strength, simple function tests , increased risk of hospitalization and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg extensor Power Rig test</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>An instrument for measuring muscle strength in the lower extremities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isometric muscle strength</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Measurement of isometric muscle strength m. quadriceps in a seated leg press.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Armflexion Test:</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Measures of overall strength in the upper extremities. The number of times the participant can inflect the elbow with dumbbell is measured in 30 sec.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-minute knee lift test:</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Measures aerobic capacity in the elderly. Number of high knee lifts in 2 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2,45minute up-and-go test:</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Target for basic mobility in the elderly. Time it takes to rise from a chair, walk around a cone 2,45m away, go back and sit down again. Moderate to good correlation between the corresponding 3m test and Berg Balance Scale (r = 0.81), walking speed (r = 0.61) and Barthel index (r = 0.78) and a good test-retest- reliability (ICC = 0.98).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DXA scan</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Lean body mass. Measurement of fat and fat-free mass and total bone mass (BMC). Executed only at baseline and at study end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion</time_frame>
    <description>Of the spine, distal forearm bilaterally, total hip bilaterally and in the skeleton as a whole (total body). In case of osteoporosis treatment will be initiated following the department's usual guidelines, which can blur the results for bone density.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory (MDI):</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Questionnaire on depression and mental well-being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA):</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>A cognitive screening test that provides an estimate of the intellectual functioning; This test is also sensitive to mild cognitive problems and dementia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life EQ-5D:</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Questionnaire on the experienced quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified PISQ-12:</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>An assessment of sexual performance (potency) and sexual desire. There are previously found improved sexual function, mood, muscle strength and body composiAn evaluation questionnaire of sexual function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aastrands Test:</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Sub-maximal fitness test performed on a treadmill. Includes monitoring heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of the Heart Rate Variability (HRV)</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Studies have indicated that hypogonodal men can improve the Heart Rate Variability by testosterone treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual-energy X-ray absorptiometry</measure>
    <time_frame>At baseline, 1 month, 5 months (at study completion)</time_frame>
    <description>Measurement of the body composition bioimpedance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood pressure</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
    <description>Blood pressure. Blood samples: Serum testosterone, hemoglobin, hematocrit, lipid profile, Potassium, Natrium, creatinine, CRP, AST, bilirubin, alkaline phosphatase, TSH, p-ionized calcium, PTH, Ca ++, and 25-OH vitamin D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
    <description>Measuring a lot of posssible side effects to training and testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - testosterone level</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - hemoglobin level</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - hematocrit level</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - lipid profile</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - Potassium</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - Natrium</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - creatinine</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - CRP</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - Aspartate aminotransferase (AST)</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - bilirubin</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - alkaline phosphatase</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - Thyreoid Stimulating Hormone (TSH)</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - p-ionized calcium</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - PTH</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - Ca ++</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters - blood sample - 25-OH vitamin D.</measure>
    <time_frame>Measured every four weeks through the study (for 5 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A control group, which is 20 weeks with placebo injections without training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A testosterone group given 20 weeks on testosterone injections without training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Training Group, which is 20 weeks with placebo injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone and training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A combination group that is 20 weeks with testosterone injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone</intervention_name>
    <description>Testosterone supplemented in 5 months</description>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_label>Testosterone and training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Progressive muscle training</intervention_name>
    <description>Progressive muscle training during 4 months</description>
    <arm_group_label>Training</arm_group_label>
    <arm_group_label>Testosterone and training</arm_group_label>
    <other_name>Training</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Living in their own home or in sheltered accommodation. Independent gait possible. with
        tool. Capable of stand-up and sit in a chair at least 8 times in 30 sec. There must be at
        least 3 symptoms or objective findings of low testosterone . Serum testosterone &lt;10nmol /L
        as the average of two independent measurements

        Exclusion Criteria:

        Known or previous prostate cancer. Abnormally elevated serum PSA (PSA = prostate specific
        antigen) corresponding to PSA&gt; 5 ng / ml or PSA&gt; 0.15 ng / ml / cc (relative to the
        prostatic volume in cubic centimeters (cc)). HÃ¦matomacrose. Heart disease in the form of:
        peri-, myo-, or endocarditis, angina, severe heart failure (NYHA class III and IV), severe
        hypertension (systolic blood pressure&gt; 180 or diastolic BT&gt; 105 mmHg after antihypertensive
        therapy). Dyspnoea at rest. Liver (AST&gt; 2 x ULN) or renal impairment (serum creatinine&gt; 200
        micromoles / L). Severe and insufficiently treated epilepsy or migraine. Insulin treatment.
        Previous or current bifosfonat-, fluoride, HRT, SERM-, strontium, teraparatid- or more than
        3 weeks of prednisolone. Joint disease with acute inflammation. Active cancer disease in
        chemo- or radiotherapy. Bone metabolic disease apart from age-related osteoporosis.
        Autoimmune diseases, chronic systemic diseases (cirrhosis, AIDS, chronic renal failure).
        Primary testosterone deficiency in the form of testicular dysgenesis, Klinefelter syndrome
        (47, XXY), 46, XX males, LH-resistance, the Y chromosome deletions, other sex chromosome
        abnormalities ,. Significant abuse, mental illness, dementia, physical disability with
        inability to implement intervention or tests or to give informed consent. Contraindications
        to testosterone undecanoate is included in the exclusion criteria, such as. presence of
        liver tumors, breast and prostate cancer, as subjects will be examined before the trial
        starts.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karsten Overgaard, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Herlev Hospital, Neurological Department N108</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karsten Overgaard, M.D.</last_name>
    <phone>+45 2617 2611</phone>
    <email>karstenovergaard20@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rune S. Rasmussen, MA, PhD</last_name>
    <phone>+45 2875 7500</phone>
    <email>rsr@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karsten Overgaard</name>
      <address>
        <city>Hellerup</city>
        <state>Danmark</state>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Overgaard, neurologist</last_name>
      <phone>+45 2617 2611</phone>
      <email>karstenovergaard20@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rune Rasmussen, PhD neuropsy</last_name>
      <phone>+45 2875 7500</phone>
      <email>rsr@sund.ku.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Mette Midttun, M.D. DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Dept. O, Geriatric Section</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Midttun, MD, DMSc</last_name>
      <phone>+45 38689188</phone>
      <email>mette.midttun@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Mette Midttun, MD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Rune Skovgaard Rasmussen</investigator_full_name>
    <investigator_title>Neuropychologist, Ph.D., associate professor</investigator_title>
  </responsible_party>
  <keyword>older</keyword>
  <keyword>frail</keyword>
  <keyword>men</keyword>
  <keyword>progressive muscle training</keyword>
  <keyword>muscle training</keyword>
  <keyword>exercise</keyword>
  <keyword>testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

